After Stock Plunges, Maybe Affymax News Isn't So Bad?
Investors didn’t like the news from drug maker Affymax (NASDAQ:AFFY) Thursday morning. The company’s pilot program for the injected treatment Omontys in kidney failure patients won’t be expanded at one of the largest chains of dialysis centers in the US according to a securities filing. The company’s shares plunged more than 30%. But the news from Affymax wasn’t that bad. A pilot program involving patients of Fresenius Medical Care (NYSE:FMS) is indeed being paused but a letter from the big dialysis company doesn’t indicate a negative reason for the action. In July Fresenius agreed to use Omontys to treat ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here